Physician profile
Jule Miller
NPI 1073533196
$2,550.56
in general payments reported to CMS, 2019-2025
14 companies · $364 in 2025
The $364 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $876 · 2020: $457 · 2021: $213 · 2022: $234 · 2023: $369 · 2024: $37.77 · 2025: $364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $770.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $676.28 | 2021-2025 | |
| Allergan, INC. | $364.13 | 2019-2020 | |
| Alkermes, INC. | $270.37 | 2019-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $253.79 | 2019-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $243.76 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $218.41 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $139.71 | 2022-2025 | Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $119.79 | 2020-2025 | Caplyta |
| Lundbeck LLC | $63.61 | 2019-2025 | Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $62.69 | 2025 | Cobenfy |
| Medline Industries LP | $55.46 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $35.09 | 2019 | |
| Vanda Pharmaceuticals INC. | $33.97 | 2019 | |
| Shire North American Group INC | $13.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jule Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.